Management of Chronic Kidney Disease Stages 1–3
Clinical Bottom Line: Risk for Mortality in Patients With CKD Stages 1–3 Treated With Beta-Blockers
Beta-blocker treatment versus placebo reduced the risk for all-cause mortality by 31 percent in patients with congestive heart failure and impaired eGFR, most of whom already were treated with an ACEI or an ARB (low strength of evidence). Patients with systolic congestive heart failure may already have an indication for beta-blockers, regardless of whether they have CKD.
95% CI = 95-percent confidence interval; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; ARR = absolute risk reduction; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; RR = risk ratio
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.